NCT Number: NCT01826994
Incremental Value of Point of Care H-FABP Testing in Primary Care Patients Suspected of Acute Coronary Syndrome
Rationale:
Thoracic complaints, possibly due to a cardiac ischemic cause are a diagnostic challenge in general practice. When an underlying ischemic cardiac condition (AMI (acute myocardial infarction), UAP (unstable angina pectoris)) is considered, referral from general practitioner (GP) to a cardiologist has to take place. However, cardiac analysis in 80% of referred patients is negative. To optimize referral decisions of GPs, new and fast diagnostics are needed.
Objective:
To assess the incremental diagnostic value for AMI of a novel rapid PoC H-FABP-test in addition to history taking and physical examination in patients presenting in daily general practice with possible AMI. In addition the cost-effectiveness of the test will be evaluated.
Study design:
Delayed type cross-sectional diagnostic study.
Study population:
Patients presenting to the GP with any new-onset chest complaint, at time of presentation not lasting for more than 24 hours, that is considered to be of possible cardiac origin by the GP.
Intervention:
Point of care Heart Type Fatty Acid Binding Protein test (PoC H-FABP-test), added to usual care. PoC H-FABP-testing, by qualitatively measuring H-FABP in one single drop of blood obtained by finger prick, is added to normal procedures of consultation and referral decision by the GP.
Main study parameters / endpoints:
Sensitivity, specificity, positive and negative predictive value of point of care H-FABP-testing for AMI, alone as well as part of a clinical diagnostic algorithm, in patients with thoracic complaints in general practice. All outcome measures, based on using an algorithm and/or point of care H-FABP-testing, will be compared to regular diagnostic assessment by the GP without using an algorithm and/or point of care H-FABP-testing. Therefore, incremental value of H-FABP-testing and/or a diagnostic algorithm is measured.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
Individual participants will experience low risk, since study participation comprehends regular care except for an extra finger prick and possibly collection of one extra venous blood sample. For this low amount of disadvantage, the participant will experience no advantage either. However, results of the study will possibly be useful for similar patients in future.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
ACHG, Leuven, Vlaams Brabant, Belgium
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- new-onset chest complaint, considered to be of possible cardiac origin by the general practitioner
- In case of death of identified cause patients are included as well.
Exclusion criteria
- all attention has to be on acute support for the patient
- symptoms are present for more than 24 hours
- oral informed consent is not given during presentation
- written informed consent is refused afterwards
- a traumatic cause is present
- complaints are presented that can be regarded as a recurrence of earlier complaints with clear diagnosis in the past
- death of unidentified cause.
Treatment and study plan
Primary outcomes
-
diagnostic value of point of care heart type fatty acid binding protein testing for acute myocardial infection, alone as well as in combination with a clinical diagnostic algorithm
Time frame: one and a half year
Sensitivity, specificity, positive and negative predictive value of point of care heart type fatty acid binding protein testing for acute myocardial infection, alone as well as in combination with a clinical diagnostic algorithm. To determine influence of sex, age, duration of the complaints, and kidney function on clinical performance of heart type fatty acid binding protein testing, subgroup analysis within our study population will be performed
Secondary outcomes
-
cost-effectiveness
Time frame: one and a half year
An economic evaluation by means of an incremental cost-effectiveness ratio will be performed. This evaluation will be performed by determination of the ratio between the difference in costs and the difference in benefits between the two strategies that are observed in this study, being the usual reference policy of the general practitioner and the reference policy that could be created when a determined algorithm combined with point of care heart type fatty acid binding protein testing would be used.
-
definition of an algorithm towards diagnosing acute coronary syndrome and unstable angina
Time frame: one and a half year
Predictive value of a diagnostic algorithm towards diagnosing acute coronary syndrome and unstable angina is determined, since unstable angina is a condition without rise in biomarkers, but should not be missed by a general practitioner assessing thoracic complaints
Sponsors and collaborators
Lead sponsor
Maastricht University Medical Center
Other
Collaborators
- FABPulous B.V.
Registry information
Official study title
Incremental Value of Heart-type Fatty Acid-Binding Protein (H-FABP) in Evaluating Patients Presenting With Symptoms Possibly Matching Acute Coronary Syndrome in Primary Care
Acronym: RAPIDA
Important dates
- Study start
- 2013
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Apr 9, 2013
- Registry last updated
- Apr 11, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Distal vs. Forearm Radial Artery Access
NCT04125992
Acute Coronary Syndrome, Angina Pectoris
Nablus, Palestinian Territories
View Trial DetailsCompressive Elastic Dressing Versus TR Band
NCT05409716
Acute Coronary Syndrome, Angina Pectoris
Nablus, West Bank, Palestinian Territories
View Trial DetailsA Trial of Everolimus-eluting Stents and Paclitaxel-eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial
NCT01016041
Acute Coronary Syndrome, Angina Pectoris
Rotterdam, Netherlands
View Trial DetailsLow Rate Fluoroscopy to Reduce Radiation Dose During Coronary Angiography and Intervention
NCT01990924
Acute Coronary Syndrome, Angina Pectoris
Québec, Quebec, Canada
View Trial Details